Trademark Overview
On Tuesday, January 13, 2026, a trademark application was filed for THERAPEUTIC TARGETING (THETA) with the United States Patent and Trademark Office. The USPTO has given the THERAPEUTIC TARGETING (THETA) trademark a serial number of 99591522. The federal status of this trademark filing is EXAMINERS AMENDMENT - MAILED as of Tuesday, July 7, 2026. This trademark is owned by Korsana Biosciences, Inc.. The THERAPEUTIC TARGETING (THETA) trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Pharmaceutical preparations for the treatment of neurological conditions, neurodegenerative conditions, central nervous system (CNS) conditions, cardiac conditions, muscle conditions, bone marrow conditions, and tumors; Drug delivery agents consisting of antibodies or antibody fragments, sold as an integral component of pharmaceuticals; Antibodies and antibody fragments for therapeutic purposes; Antibody-drug conjugates for the treatment of neurological conditions, neurodegenerative conditions, central nervous system (CNS) conditions, cardiac conditions, muscle conditions, bone marrow conditions, and tumors; Antibody fragment-drug conjugates for the treatment of neurological conditions, neurodegenerative conditions, central nervous system (CNS) conditions, cardiac conditions, muscle conditions, bone marrow conditions, and tumors
Pharmaceutical research and development
